Skip to main content
OpenTrials
Completed

NCT Number: NCT05789810

Manual Pressure and ShotBlocker to Reduce Needle-Related Pain and Fear

This experimental, prospective, and randomized controlled study was designed to determine and compare the effects of applying manual pressure and ShotBlocker methods in reducing pain and fear during the subcutaneous insulin injection for children with Type 1 diabetes mellitus. A parallel trial design was used describing two intervention (manual pressure and ShotBlocker) and a control group (no intervention used) as the third arm. The study population consisted of children aged 6-12 years, diagnosed with Type 1 diabetes mellitus, administered insulin injections, able to cognitively score their pain and fear levels, who wanted to participate in the study, and gave verbal and written consent to participate in the study.The study sample composed of 90 children based on confidence interval of 95% and statistical power of 80%. Each intervention and control group was matched in terms of gender. In the study, the randomization of the sample group was performed by using stratification and block randomization methods.

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 year–12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Çankırı Karatekin Univesity

Çankiri, 18200, Turkey (Türkiye)

About this study

This experimental, prospective, and randomized controlled study was designed to determine and compare the effects of applying manual pressure and ShotBlocker methods in reducing pain and fear during the subcutaneous insulin injection for children with Type 1 diabetes mellitus. A parallel trial design was used describing two intervention (manual pressure and ShotBlocker) and a control group (no intervention used) as the third arm. The study sample composed of 90 children based on confidence interval of 95% and statistical power of 80%. In post-hoc analysis made using G power 3.1 software, the power of sample size including 90 children with α = .05 and effect size (w)= .31, was 1 - β = 0.87. Power of .80 or higher is indicative of an adequate sample size. In addition, in order to prevent bias and increase the validity of the data, the pain and fear scores of the children before and after the procedure were assessed by three different groups as children (n:90), their parents (n:90), and a researcher specialized in pediatric nursing (the first author; n:1), and the inter-observer agreement was examined. The parents meeting the following inclusion criteria were eligible for the participation: 1) being healthy in terms of neurological functions, 2) communicating verbally, 3) understanding and reading Turkish, and 4) voluntarily signing the written informed consent. The children were first categorized according to their genders and then assigned into three study groups by using block randomization method to control the effect of gender on pain. First, the numbers 1, 2 and 3, representing the three groups, were written on paper of the same color and shape and put in a pink box for girls and blue for boys.After, female children were asked to draw a piece of paper from the pink box and male children were asked to draw a piece of paper from the blue box to provide a randomized distribution and to reduce all negative effects. Thus, the groups became self-balanced. Intervention and control groups were matched in themselves based on gender, each group included a total of 30 children including 15 girls and 15 boys. The study was conducted in accordance with the CONSORT guideline for reporting the randomized controlled trials.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

administered insulin injection, able to score cognitively pain and fear levels, who want to participate in research children who gave verbal and written consent to participate in the study

Exclusion criteria

Having pacemaker and neurodevelopmental disorder, having lipodystrophy, infection and nerve damage in the injection area, administered analgesics in the last 6 hours, admitted to the outpatient clinic with a picture of ketoacidosis, Diagnosed with Reynaud's syndrome and sickle cell anemia children who do not want to participate in the research

Treatment and study plan

Manuel pressure

Other

10-second manual pressure was applied on the insulin injection area.

shotblocker

Other

ShotBlocker device was placed in the insulin injection site by contacting the protruding surface with the skin and was kept throughout the injection. The injection was applied through the opening at the middle of the tool.

Control

Other

No intervention was performed to reduce pain and fear.

Primary outcomes

  1. Pain Severity

    Time frame: 5 Months

    Wong-Baker FACES Pain Rating Scale was used to assess the pain levels of children before and after the insulin administration. This scale was administered to the children, their parents, and a researcher (the first author) within 5 minutes before and immediately after the insulin administration. The scale was scored blindly before and after the insulin administration so that they were not affected by each other.

  2. Fear Severity

    Time frame: 5 Months

    Child Fear Scale was used to assess pain-related fear levels of children before and after the insulin administration. This scale was administered to the children, their parents, and a researcher (the first author) within 5 minutes before and immediately after the insulin administration. The scale was scored blindly before and after the insulin administration so that they were not affected by each other.

Sponsors and collaborators

Lead sponsor

Çankırı Karatekin University

Other

Collaborators

  • Istanbul Saglik Bilimleri University

Registry information

Official study title

Effects of Applications Manual Pressure and ShotBlocker to Reduce Needle-Related Pain and Fear in Children With Type 1 Diabetes Mellitus

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Mar 29, 2023
Registry last updated
Mar 29, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.